Research by the World Health Organization (WHO) states that around 17 million deaths have been noticed annually due to strokes. The higher mortality rate associated with strokes showcases an impending need for new and innovative drugs and diagnostic devices. As per the latest report released by Market Research Future (MRFR), the Global Ischemic Stroke Market Size is expected to attain a CAGR of approximately 7.8% during the forecast period between 2023 and 2032.
The
Ischemic stroke market is a dynamic landscape shaped by various factors,
including advancements in treatment options and the prevalence of risk factors
such as transient ischemic
attacks (TIAs). TIAs, often referred to as "mini-strokes,"
serve as crucial indicators of impending ischemic strokes, highlighting the
importance of timely intervention and management strategies within the market.
Healthcare providers and pharmaceutical companies within this market are
increasingly focusing on addressing the needs of patients who have experienced
TIAs to prevent the occurrence of debilitating ischemic strokes. As such, there
is a growing emphasis on developing innovative diagnostic tools and therapeutic
interventions tailored to the unique challenges posed by TIAs, aiming to reduce
the overall burden of ischemic stroke on both patients and healthcare systems.
Furthermore,
the recognition of TIAs as warning signs for more severe ischemic strokes has
led to heightened awareness among both healthcare professionals and the general
population. This increased awareness has driven efforts to enhance preventive
measures and promote early detection and treatment of TIAs, thereby potentially
reducing the incidence of ischemic strokes. Consequently, stakeholders within
the Ischemic stroke market are continually investing in research and
development endeavors focused on improving TIA management strategies,
ultimately contributing to better patient outcomes and a more efficient
healthcare ecosystem dedicated to combating ischemic strokes.
Competitive Landscape
The
Global Ischemic Stroke
Companies includes numerous prominent players like Stryker Corporation (U.S.),
Johnson & Johnson (U.S.), Abbott Laboratories (U.S.), Genentech, Inc.
(U.S.), Merck & Co., Inc. (U.S.), Sanofi (France), Bayer AG (Germany),
Koninklijke Philips N.V. (Netherland), Boston Scientific Corporation (U.S.),
Medtronic plc (U.S.), Siemens Healthcare (U.S.), Pfizer Inc. (U.S.), GE
Healthcare (U.S.), Covidien PLC (Ireland), GE Healthcare (U.S.), Philips
Healthcare (U.S.), Hitachi, Ltd (Japan), Boehringer Ingelheim (Germany), Penumbra,
Inc. (U.S.), Cordis Corporation (U.S.), Daiichi Sankyo (U.S.), Biogen
(U.S.), and others.
Market Segmentation
The
Global Ischemic Stroke Market segmentation is based on key dynamics
like drug class, diagnosis, end-users, and surgery.
- By drug class, the market
segments into anticoagulant, tissue plasminogen activator,
antihypertensive, antiplatelet, and others.
- By diagnosis, the market
includes carotid ultrasound Computed Tomography (CT), echocardiography,
cerebral angiography, Magnetic resonance imaging (MRI),
electrocardiography, and others.
- By end-user, the market
comprises of medical institutes, research organizations, hospitals &
clinics, and others.
- By surgery, the market
divides into endovascular mechanical thrombectomy, carotid endarterectomy,
and angioplasty.
Regional Analysis
The
Global Ischemic Stroke Market is geographically segmented into the following
regions: Asia Pacific, America, Europe, and the Middle East and Africa.
The
Americas is reported to be the largest market for ischemic stroke due to
technological innovations, favorable government initiatives, and rising demand
for ischemic stroke products.
Europe
holds the second largest share of the market and is expected to hold on to the
same in the forthcoming years due to numerous factors. Rising prevalence of
acute ischemia stroke cases and advancements in the surgical device technology
are two key factors driving the market herein. Other driving factors of the
market in this region is the growing number of diabetes mellitus population
primarily in the developed nations of Europe.
Asia
Pacific is identified to witness the most promising growth in the forecast
period to cement its place in the global ischemic stroke market. The
proliferating growth of the region can be attributed to the widespread
prevalence of stroke cases in the Asia Pacific region. Both China and India are
two of the major contributors to the regional market and will play major roles
in accelerating the overall Asia Pacific region. Manufacturers are quickly
realizing the potential this region holds and are expanding their operations
therein to capitalize on the same.
The
Middle East region is anticipated to grow at a fast rate owing to factors like
increasing emphasis on research and development activities in the healthcare
sector and continuous development of the healthcare infrastructure.
No comments:
Post a Comment